BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31483507)

  • 1. Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?
    Moser S; Bacher U; Jeker B; Mansouri Taleghani B; Betticher D; Ruefer A; Egger T; Novak U; Pabst T
    Hematol Oncol; 2019 Dec; 37(5):649-651. PubMed ID: 31483507
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.
    Amsler IG; Jeker B; Mansouri Taleghani B; Bacher U; Betticher D; Egger T; Zander T; Luethi JM; Novak U; Pabst T
    Leuk Lymphoma; 2019 Feb; 60(2):511-514. PubMed ID: 30616438
    [No Abstract]   [Full Text] [Related]  

  • 3. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.
    Mohyuddin GR; Faisal MS; Badar T; Shah N; Bashir Q; Patel KK; Hosing C; Popat UR; Rondon G; Delgado R; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2018 Feb; 59(2):515-518. PubMed ID: 28673185
    [No Abstract]   [Full Text] [Related]  

  • 4. Autologous Hematopoietic Cell Transplantation for Dialysis-Dependent Myeloma: More Efficient, Less Toxic.
    Amit O; Ram R
    Acta Haematol; 2018; 139(2):104-105. PubMed ID: 29414800
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.
    Nicol C; Henry C; Couturier MA; Delépine P; Tripogney C; Buors C; Guillerm G; Berthou C; Tempescul A; Ianotto JC
    Leuk Lymphoma; 2017 Sep; 58(9):1-3. PubMed ID: 28278727
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantation.
    Mai EK; Schmitt T; Radujkovic A; König L; Goldschmidt H; Ho AD; Luft T; Müller-Tidow C; Dreger P; Hegenbart U; Schönland SO
    Br J Haematol; 2022 Jan; 196(1):244-248. PubMed ID: 34431093
    [No Abstract]   [Full Text] [Related]  

  • 8. Autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Attal M; Harousseau JL
    Baillieres Best Pract Res Clin Haematol; 1999; 12(1-2):171-91. PubMed ID: 11000991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of stem cell transplantation in myeloma.
    Gahrton G; Iacobelli S; Björkstrand B; Bourhis J; Corradini P; Crawley C; Morris C; Niederwieser D;
    Hematology; 2005; 10 Suppl 1():127-8. PubMed ID: 16276618
    [No Abstract]   [Full Text] [Related]  

  • 11. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
    D'Souza A; Pasquini M; Logan B; Giralt S; Krishnan A; Antin J; Howard A; Goodman S; Qazilbash M; Knust K; Sahebi F; Weisdorf D; Vesole D; Stadtmauer E; Maloney D; Hari P
    Br J Haematol; 2017 Sep; 178(5):816-819. PubMed ID: 27292583
    [No Abstract]   [Full Text] [Related]  

  • 12. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.
    Kawamura K; Ikeda T; Hagiwara S; Mori T; Shinagawa A; Nishiwaki K; Ohashi K; Kubonishi S; Fukuda T; Ito T; Tomita N; Ichinohe T; Kato K; Morishima Y; Atsuta Y; Sunami K; Kanda Y
    Leuk Lymphoma; 2016 Sep; 57(9):2077-83. PubMed ID: 26961137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage second transplantation in relapsed multiple myeloma.
    Dhakal B; D'Souza A; Kleman A; Chhabra S; Mohan M; Hari P
    Leukemia; 2021 Apr; 35(4):1214-1217. PubMed ID: 32747684
    [No Abstract]   [Full Text] [Related]  

  • 14. Autologous stem-cell transplantation in multiple myeloma.
    Gahrton G
    Wien Med Wochenschr; 1995; 145(2-3):52-4. PubMed ID: 7762254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous transplantation in multiple myeloma.
    Bladé J
    Haematologica; 2006 Sep; 91(9):1157. PubMed ID: 16956811
    [No Abstract]   [Full Text] [Related]  

  • 16. The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?
    Müller AMS; Kumar SK; Bruno B
    Haematologica; 2019 Feb; 104(2):222-225. PubMed ID: 30705115
    [No Abstract]   [Full Text] [Related]  

  • 17. Tandem bone marrow transplantation in multiple myeloma.
    Murashige N; Kishi Y
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15070801
    [No Abstract]   [Full Text] [Related]  

  • 18. Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.
    Stettler J; Novak U; Baerlocher GM; Seipel K; Mansouri Taleghani B; Pabst T
    Leuk Lymphoma; 2017 May; 58(5):1076-1083. PubMed ID: 27736269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When to recommend a second autograft in patients with relapsed myeloma?
    Ziogas DC; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2017 Apr; 58(4):781-787. PubMed ID: 27894207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.